Clinical trials: Botulinum Toxin Type A
- Condition Botulinum Toxin Type A
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Lateral Canthal Lines, Crow's Feet
Dose Finding Study In Subjects With Crow's Feet
The purpose of this study is to establish the therapeutic range of ANT-1401 in the treatment of Crow's Feet.
- Trial name
- NCT01951742
- Testing
- ANT-1401, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Urinary Tract Infections
Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection
This study is a retrospective record review to determine whether a novel multiplex PCR assay can be utilized as a screening method for UTI in patients receiving Botox injection to treat overactive bladder (OAB).
- Trial name
- NCT04817865
- Testing
- Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pathnostics
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.
- Trial name
- NCT07622004
- Testing
- Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- INIBIO Co., Ltd.
Lateral Canthal Lines, Crow's Feet
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968942
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Facial Fine Lines
Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines
The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.
- Trial name
- NCT04631588
- Testing
- Botox
- Where
- 5 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Allergan
Healthy
Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers
This study will determine the pharmacodynamic and safety of MEDITOXIN® in healthy male volunteers.
- Trial name
- NCT03317717
- Testing
- Meditoxin, Botox
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03736928
- Testing
- AbobotulinumtoxinA dose level 1 or 2, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
- Where
- 10 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Healthy
Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening.
- Trial name
- NCT00515944
- Testing
- Botulinum neurotoxin type A, free of complexing proteins
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a…
- Trial name
- NCT05364580
- Testing
- PROTOXIN, Botox®
- Where
- 5 sites in South Korea
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Cervical Dystonia
Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia
To determine the efficacy and safety of Botulax® in treatment of cervical dystonia
- Trial name
- NCT04171258
- Testing
- Botulinum toxin type A injection, Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hugel
Glabellar Lines
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT02961673
- Testing
- HU-014 Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Glabellar Frown Lines
The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
This clinical trial is an extended clinical trial for test subjects who participated in the phase 3 clinical trial of PT_BTA_P3_21 (clinical trial plan number) and completed follow-up observation up to 16 weeks after…
- Trial name
- NCT06124794
- Testing
- PROTOXIN
- Where
- 3 sites in South Korea
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Glabellar Lines, Wrinkles
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
This study is designed to evaluate the safety, efficacy, and subject and investigator satisfaction of 2 different injection volumes of Dysport in the glabellar lines. 1.
- Trial name
- NCT02718118
- Testing
- Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
- Trial name
- NCT04830345
- Testing
- ATGC-100 100U, Botox 100U
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Moderate to Severe Glabellar Lines
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 3, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate the efficacy and safety of 50 units (U) of QM1114-DP for the treatment of moderate to severe GL in male and…
- Trial name
- NCT05463965
- Testing
- QM1114-DP, OnabotulinumtoxinA
- Where
- 6 sites in China
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabella Line Severity
Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)
This study design is multi-center, randomized, double-blind, parallel group, active controlled, phase 3 clinical trial(Including randomized, double-blind, parallel group, active controlled, preliminary study).
- Trial name
- NCT03894748
- Testing
- Botulinum Toxin Type A
- Where
- 3 sites in South Korea
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Lateral Canthal Lines, Crow's Feet
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the efficacy and safety of a single administration of RT001 compared to placebo gel for the treatment of moderate to severe lateral canthal lines.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968825
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Masseter Muscle Prominence
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Based on the results of the Phase 2 Study 191622-130 [NCT02010775], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT03861936
- Testing
- OnabotulinumtoxinA, Normal saline
- Where
- 14 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Allergan